Free Trial
NYSE:VOR

Vor Biopharma (VOR) Stock Price, News & Analysis

$0.94
-0.01 (-1.05%)
(As of 07/24/2024 ET)
Today's Range
$0.93
$0.98
50-Day Range
$0.91
$1.81
52-Week Range
$0.90
$3.18
Volume
172,239 shs
Average Volume
322,263 shs
Market Capitalization
$64.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50

Vor Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,223.0% Upside
$12.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$20,357 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.49) to ($1.24) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.60 out of 5 stars

Medical Sector

419th out of 901 stocks

Biological Products, Except Diagnostic Substances Industry

1st out of 1 stocks

VOR stock logo

About Vor Biopharma Stock (NYSE:VOR)

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

VOR Stock Price History

VOR Stock News Headlines

Forecaster with 99.8% Accuracy Makes Shocking Prediction
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Forecaster with 99.8% Accuracy Makes Shocking Prediction
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
See More Headlines
Receive VOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vor Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
7/24/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
N/A
Sub-Industry
N/A
Fax
N/A
Employees
168
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.50
High Stock Price Target
$17.50
Low Stock Price Target
$10.00
Potential Upside/Downside
+1,202.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
65,052,000
Market Cap
$65.53 million
Optionable
Not Optionable
Beta
-0.34
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

Key Executives

  • Dr. Robert Ang M.B.A. (Age 49)
    M.D., MBBS, President, CEO & Director
    Comp: $943.91k
  • Dr. Tirtha Chakraborty Ph.D. (Age 51)
    Chief Scientific Officer
    Comp: $661.98k
  • Dr. Eyal C. Attar M.D. (Age 53)
    Chief Medical Officer
    Comp: $660.55k
  • Dr. Siddhartha Mukherjee DPHIL (Age 53)
    M.D., Ph.D., Scientific Founder & Chairman of Scientific Advisory Board
  • Dr. Nathan D. Jorgensen M.B.A. (Age 47)
    Ph.D., Chief Financial Officer
    Comp: $608.48k
  • Ms. Tania Philipp (Age 52)
    Chief People Officer
  • Mr. John C. King M.B.A. (Age 48)
    Chief Commercial Officer
  • Mr. Samir Vattompadam M.S.
    Senior Vice President of Portfolio Strategy & Program Management
  • Mr. David Phillips M.B.A.
    Senior VP & Head of Quality

VOR Stock Analysis - Frequently Asked Questions

How have VOR shares performed this year?

Vor Biopharma's stock was trading at $2.25 on January 1st, 2024. Since then, VOR shares have decreased by 58.0% and is now trading at $0.9448.
View the best growth stocks for 2024 here
.

How were Vor Biopharma's earnings last quarter?

Vor Biopharma Inc. (NYSE:VOR) announced its quarterly earnings results on Thursday, May, 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.08.

When did Vor Biopharma IPO?

Vor Biopharma (VOR) raised $150 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel served as the underwriters for the IPO.

How do I buy shares of Vor Biopharma?

Shares of VOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:VOR) was last updated on 7/24/2024 by MarketBeat.com Staff

From Our Partners